Sinphar Pharmaceutical Co has a quick ratio of 1.78. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sinphar Pharmaceutical Co's Quick Ratio or its related term are showing as below:
TPE:1734'
s Quick Ratio Range Over the Past 10 Years
Min: 1.31 Med: 1.49 Max: 2.04
Current: 1.78
During the past 13 years, Sinphar Pharmaceutical Co's highest Quick Ratio was 2.04. The lowest was 1.31. And the median was 1.49.
TPE:1734's Quick Ratio is ranked worse than 68.56% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs TPE:1734: 1.78
Sinphar Pharmaceutical Co (TPE:1734) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Sinphar Pharmaceutical Co Quick Ratio Related Terms
Sinphar Pharmaceutical Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Sinphar Pharmaceutical Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a Quick Ratio of 1.78 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 19% above median its historical median of 1.49. Over the past decade, Sinphar Pharmaceutical Co's Quick Ratio has ranged from 1.31 to 2.04. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #968 out of 1412 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Sinphar Pharmaceutical Co's Quick Ratio too high?
Sinphar Pharmaceutical Co's current Quick Ratio of 1.78 is 19% above median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 2.04. The Biotechnology industry median Quick Ratio is 3.60. Sinphar Pharmaceutical Co's value of 1.78 is 50.6% below this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #968 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #968 out of 1412 companies for Quick Ratio. This places Sinphar Pharmaceutical Co in the lower half of its industry. The industry median Quick Ratio is 3.60. Sinphar Pharmaceutical Co's value of 1.78 is 50.6% below this benchmark. Historically, Sinphar Pharmaceutical Co's own Quick Ratio has ranged from 1.31 to 2.04 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 3.60, Sinphar Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current Quick Ratio of 1.78 is 50.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current Quick Ratio is 1.78, which is 19% above median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$32.80 — trading 1% below its estimated fair value. The current Quick Ratio is 1.78, which is 19% above median its 10-year median of 1.49 and 50.6% below the Biotechnology industry median of 3.60. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Quick Ratio is 1.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$32.80 is trading 1% below its estimated GF Value™ of NT$33.14.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
Quick Ratio: 1.78 (19% above median its 10-year median of 1.49)
GF Value™: NT$33.14 vs. price of NT$32.80 (1% below fair value)
Industry Position: 50.6% below the Biotechnology median (#968 of 1412)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
